UK’s NHS Facing Major Leadership Shake-Up
After several scandals that revealed longstanding deficiencies and a continual churn of executive staff, a recent independent review of leadership in the National Health Service (NHS) has uncovered a lack…
Address: First Floor, Building 2,
Croxley Green Business Park,
Marlins Meadows
Watford, Hertfordshire
United Kingdom – WD18 8YA
Tel: +44 (0) 1923 202 950
Web: http://eu.glenmark-generics.com/
Glenmark Generics (Europe) Ltd headquartered in the UK operates through its own sales infrastructure in the UK and through licensing & distribution arrangements in other European markets.
The UK office based in Hatfield, Hertfordshire possesses the infrastructure to support licensing, regulatory submissions, project management, distribution of sales in the UK and across Europe.
Glenmark is building its presence in markets across Europe and seeks out opportunities to develop strategic alliances and marketing collaborations with leading generic companies operating in the EU markets.
Glenmark was awarded the prestigious SCRIP award in 2008 for the Best Pharma company in the world – SME & the Best Company in Emerging Markets.
Glenmark Generics (Europe) Ltd has an exciting portfolio of 5 approved products, 12 products filed and pending approval; with a further 15 products in development. These are solid and semi-solid products filed as EU CTD dossiers and offered for out-licensing to prospective partners. Most of the portfolio are backed up with vertical integration on APIs.
After several scandals that revealed longstanding deficiencies and a continual churn of executive staff, a recent independent review of leadership in the National Health Service (NHS) has uncovered a lack…
Just one year after the UK government published its Life Science Vision, outlining the ambitions of the government and the life science sector for the next 10 years, the Association…
After a tumultuous year, AstraZeneca is creating a standalone vaccine unit and will begin to charge for its COVID-19 vaccine shot, having previously provided it at cost. PharmaBoardroom looks back…
The latest news from UK pharma, including AstraZeneca’s decision to create a dedicated business unit for its COVID-19 vaccines, GSK’s raised profits forecast, and CDMO Almac’s move to create over…
Cyril Titeux, senior VP mid-sized markets EMEA & strategic leader at Janssen, argues that the current focus of many health systems on efficiency, streamlining, and reducing spending is leaving them…
British pharmaceuticals giant, GSK, one of the UK’s largest companies by market capitalization, is once again finding itself under the spotlight as analysts and shareholders alike continue to query the…
Kathy Pritchard-Jones, Professor of Paediatric Oncology at University College London (UCL) and President of the International Society of Paediatric Oncology (SIOP) discusses the latest advancements in childhood cancer treatment, the…
Zack Pemberton-Whiteley, CEO of UK-based blood cancer charity Leukaemia Care, discusses the importance of patient and patient organizations’ involvement in the decision-making process for therapy appraisals, the use of HTA,…
Stuart Evans, partner at law firm BLM and specialist in commercial disputes and litigation examines the origins and fallout of the EU/AstraZeneca vaccine dispute and why the twin forces of…
The latest UK pharma news, including how new investment in GSK stands to reshape the country’s iconic pharma giant; CDMO Sterling’s latest acquisition; and calls for a national registry to…
The first day of March 2013 also marked a first for GW Pharmaceuticals. On that day, the British biopharmaceutical company successfully listed on NASDAQ, raising over USD 30 million. Founded…
When the European Medicines Agency (EMA) relocated from London to Amsterdam after the UK announced its decision to leave the European Union, some analysts feared that Britain could become left…
See our Cookie Privacy Policy Here
